within Pharmacolibrary.Drugs.ATC.L;

model L01DB11
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00022,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0314,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0415,
    k12             = 22.4,
    k21             = 22.4
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01DB11</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Pixantrone is an antineoplastic agent belonging to the class of aza-anthracenediones. It is structurally related to mitoxantrone and is used primarily for the treatment of relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. Pixantrone has been granted conditional marketing authorization in the European Union but is not FDA-approved in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult cancer patients (mostly with non-Hodgkin lymphoma) receiving pixantrone as monotherapy, intravenous administration.</p><h4>References</h4><ol><li><p>She, Z, et al., &amp; Deng, Y (2014). The anticancer efficacy of pixantrone-loaded liposomes decorated with sialic acid-octadecylamine conjugate. <i>Biomaterials</i> 35(19) 5216–5225. DOI:<a href=&quot;https://doi.org/10.1016/j.biomaterials.2014.03.022&quot;>10.1016/j.biomaterials.2014.03.022</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24703714/&quot;>https://pubmed.ncbi.nlm.nih.gov/24703714</a></p></li><li><p>Kurmasheva, RT, et al., &amp; Smith, MA (2014). Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program. <i>Pediatric blood &amp; cancer</i> 61(5) 922–924. DOI:<a href=&quot;https://doi.org/10.1002/pbc.24800&quot;>10.1002/pbc.24800</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24166988/&quot;>https://pubmed.ncbi.nlm.nih.gov/24166988</a></p></li><li><p>Dawson, LK, et al., &amp; Smyth, JF (2000). A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly. <i>European journal of cancer (Oxford, England : 1990)</i> 36(18) 2353–2359. DOI:<a href=&quot;https://doi.org/10.1016/s0959-8049(00)00342-7&quot;>10.1016/s0959-8049(00)00342-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11094309/&quot;>https://pubmed.ncbi.nlm.nih.gov/11094309</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01DB11;
